Peer Behavioral Activation Utilization to Improve Substance Use and HIV Outcomes in People Receiving Long Acting Injectable-PrEP/ART (PUSH)
University of Maryland, Baltimore · NCT06501781
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–88 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 186
- US sites recruiting
- 2
- Study start
- March 18, 2025
- Record last updated
- October 31, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This randomized Type 1 hybrid effectiveness-implementation trial (N=186) will evaluate the effectiveness and implementation of a peer-delivered problem solving and behavioral activation intervention for adherence to LAI-PrEP/ART ("Peer Activate-LAI") compared to enhanced treatment as usual (ETAU) for a largely Black, substance-using population living with or at high risk for HIV. Specific aims are to:
Aim 1: Evaluate the effectiveness of Peer Activate-LAI over 12-months on: a) LAI-PrEP/ART adherence (primary; receipt of all 6 maintenance injections within 7-day window); and b) substance use (secondary; WHOASSIST, urine toxicology); and c) Explore the moderating role of SRD-related factors (exploratory)
Aim 2: To evaluate the implementation of Peer Activate-LAI including feasibility, acceptability, fidelity, and adoption guided by RE-AIM and Proctor's model,12,13 assessed using mixed methods, including a rapid ethnographic assessment of how SRD-related factors may affect implementation.
Aim 3: To evaluate the economic viability of Peer Activate-LAI, including a) cost of implementation and sustainment, and b) cost-effectiveness from multiple stakeholder perspectives.
This study will inform a potentially scalable, cost-effective model for facilitating effective adherence to LAI formulations of PrEP/ART within Black, substance-using populations with multiple minority identities who to date have had limited support for improving LAI adherence for HIV treatment and prevention.
Being studied: Peer Activate-LAI; Standard of Care HIV treatment or prevention with LAI-PrEP/ART
Conditions: HIV Infections; Substance Use
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age 18 years or older
- Able and willing to sign informed consent
- HIV status:
HIV negative with a negative HIV antibody/antigen test and meeting CDC(center for disease control and prevention) criteria for PrEP HIV positive with a positive antibody/antigen test
- Meeting indications for treatment based on Cabotegravir-LA (HIV negative) or Cabotegravir (CAB) and Rilpivirine (RPV)-LA (HIV positive) prescribing information
- Moderate substance use, defined as a (World Health Organization Alcohol, Smoking and Substance Involvement Screening Test) WHO-ASSIST score of ≥4 for certain drugs (cocaine, amphetamines, inhalants, sedatives, hallucinogens, or opioids) or ≥11 for alcohol
Exclusion Criteria
- Contraindications to Cabotegravir-LA (HIV-) or Cabotegravir (CAB) and Rilpivirine (RPV)-LA (HIV+) use based on prescribing information or other medical/psychiatric conditions that may interfere with study participation
- Pregnant or breastfeeding
Recruiting US locations
HIPS (Harm reduction drop-in center)
Washington D.C., DC 20002
Site contact: Phyllis Bijole Clinic Manager · 202.834.3289 · phyllis@hips.org
Baltimore Safe Haven
Baltimore, MD 21218
Site contact: Onyinyechi Ogbumbadiugha, MPH · (443)-635-4943 · oogbumbadiugha@ihv.umaryland.edu
Study contacts (from the official record)
- Elana Rosenthal, MD · 240-367-4157 · erosenthal@ihv.umaryland.edu
- Emade Ebah Edongole, RN · 202-655-6229 · eebah@ihv.umaryland.edu
Similar studies in District of Columbia
All healthy volunteers studies in District of Columbia →- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Washington D.C., DC + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
International AIDS Vaccine Initiative
- Location
- Washington D.C., DC + 1 other US site
- Eligibility basics
- Ages 18–50
- RecruitingHealthy volunteersPhase 1
A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health
International AIDS Vaccine Initiative
- Location
- Washington D.C., DC + 2 other US sites
- Eligibility basics
- Ages 18–50
- RecruitingHealthy volunteersEarly Phase 1
Assistance Delivery and Muscle Coordination
The Catholic University of America
- Location
- Washington D.C., DC
- Eligibility basics
- Ages 20–80